Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Injectafer is now the first and only intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency
Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe
The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Both the companies intend to facilitate faster clinical trial enrollment and provide patients with access to novel medications
Nous-209 has been developed using the Nouscom's viral vector platform
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
Franson will help biopharma clients design a phased approach to inform and execute clinical development plans
Subscribe To Our Newsletter & Stay Updated
